2023
Young J, Wang S, Lanièce Delaunay C, Cooper CL, Cox J, Gill MJ, Hull M, Walmsley S, Wong A, Klein MB, for the Canadian Coinfection Cohort Investigators. The Rate of Hepatitis C Virus (HCV) Reinfection in Canadians Coinfected with HIV and its Implications for National Elimination. 32nd Annual Canadian Conference on HIV/AIDS Research (CAHR 2023). Quebec City, Canada, April 27-30, 2023.
Saeed S, Thomas T, Moodie EEM, Cox J, Cooper C, Gill MJ, Martel-Laferrière V, Wong A, Walmsley S, Klein MB, for the Canadian Coinfection Cohort Investigators. Lost but not forgotten: Longitudinal (dis)engagement trajectories and mortality among people living with HIV and Hepatitis C in Canada. 25th International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2023). Athens, Greece, March 23rd to 25th, 2023.
Young J, Wang S, Lanièce Delaunay C, Cooper CL, Cox J, Gill MJ, Hull M, Walmsley S, Wong A, Klein MB, for the Canadian Coinfection Cohort Investigators. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination”, 25th International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2023). Athens, Greece, March 23rd to 25th, 2023.
2021
Ortiz-Paredes D, Amoako A, Ekmekjian T, Engler K, Lebouché B, Klein MB. Interventions to Improve the Uptake of Direct-Acting Antivirals in High- and Middle-Income Countries: A Systematic Review. 9th International Conference on Health and Hepatitis Care in Substance Users (INHSU 2021 virtual). 13- 15 October 2021.
Laniece Delaunay C, Maheu-Giroux M, Marathe G, Saeed S, Cooper C, Walmsley S, Cox J, Hull M, Martel-Laferrière V, Pick N, Vachon M-L, Klein M. Assessing gaps in hepatitis C virus (HCV) prevention and care for HIV-HCV coinfected people who inject drugs in Canada. 17th Annual Student Research Day, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, March 12, 2021. Virtual meeting.
2020
Laniece Delaunay C, Maheu-Giroux M, Saeed S, Cooper C, Cox J, Hull M, Martel-Laferrière V, Moodie EEM, Vachon ML, Klein MB. Hepatitis C Virus (HCV) Treatment, Injection Practices, and Access to Harm Reduction among HIV/HCV co-infected People who Inject Drugs in Montréal from 2003-2018. 29th Annual Canadian Conference on HIV/AIDS Research (CAHR 2020), March 29 – May 3, 2020
Marathe G, Moodie EEM, Brouillette MJ, Cox J, Cooper C, Conway B, Hull M, Vachon ML, Walmsley S, Wong A, Klein MB for the Canadian Co-Infection Cohort Investigators. Development of supervised machine learning algorithms to predict the presence of clinically significant depressive symptoms in the HIV-Hepatitis C virus co-infected population in Canada. Annual Student Research Day, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, March 13, 2020
Laniece Delaunay C, Maheu-Giroux M, Saeed S, Cooper C, Cox J, Hull M, Martel-Laferrière V, Moodie EEM, Vachon ML, Klein MB. Hepatitis C Virus (HCV) Treatment, Injection Practices, and Access to Harm Reduction among HIV/HCV co-infected People who Inject Drugs in Montréal from 2003-2018. Annual Student Research Day, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montreal, March 13, 2020. (1st place winner)
2019
Palayew A, Schmidt AM, Saeed S, Cooper C, Martel-Lafferiere V, Klein MB. Estimation of an individual‑level deprivation index for HIV/HCV co‑infected persons. 8th Canadian Symposium on Hepatitis C Virus, May 24, 2019, Montreal, QC, Canada
Pearce M, Jongbloed K, Demerais L, Christian WM, MacDonald H, Sharma R, Yoshida E, Pick N, Spittal PM, Klein MB. Just knowing I don’t have hep C makes me feel like a new person : Working toward equitable access to hepatitis C treatment among Indigenous people in Canada. 28th Annual Canadian Conference on HIV/AIDS Research (CAHR 2019), May 9-12, 2019, Saskatoon, SK, Canada
Palayew A, Schmidt AM, Saeed S, Cox J, Gill J, Walmsley S, Cooper C, Wong A, Pick N, Hull M, Klein MB, on behalf of the Canadian Co-infection Cohort. Estimation of an individual-level deprivation index for HIV/HCV co-infected persons in Canada and in four provinces. 28th Annual Canadian Conference on HIV/AIDS Research (CAHR 2019), May 9-12, 2019, Saskatoon, SK, Canada
2018
Kronfli N, Nitulescu R, Cox J, Moodie EEM, Cooper C, Wong A, Walmsley S, Klein MB, on behalf of the Canadian Co-infection Cohort Investigators. Decreased Hepatitis C (HCV) Treatment Uptake among HIV-HCV Co-infected Patients with a History of Incarceration. 2018 IDIGH Research Day, Research Institute of the McGill University Health Centre. April 20, 2018, Montreal, QC
Saeed S, Wong L, Cooper C, Wong A, Barrett L, Cohen J, Conway B, Côté P, Cox J, Gill MJ, Haider S, Hull M, Martel-Laferriere V, Moodie EEM, Pick N, Rachlis A, Sadr A, Sanche S, Sandre R, Tyndall M, Vachon M-L, Walmsley S, Klein MB, for the Canadian Co-Infection Cohort Study. Is Hepatitis C Elimination Possible Among HIV-infected Population in Canada? 16th ISVHLD Global Hepatitis Summit. June 15, 2018, Toronto, ON
Saeed S, Moodie EEM, Gill MJ, Wong A, Cooper C, Walmsley S, Hull M, Martel-Lafferriere V, Strumpf EC, Klein MB for the Canadian Co-Infection Cohort Study. Real World Impact of Direct Acting Antiviral Therapy on Patient Reported Outcomes. The Canadian Association for Health Services and Policy Research Conference 2018. May 29-31, 2018, Montreal Qc
Rossi C, Young J, Saeed S, Wong L, Kronfli N, Klein MB on behalf of the Canadian Co-infection Cohort Investigators. Low Rates of Failure of Direct-Acting Antiviral Therapies for Chronic Hepatitis C among HIV Co-Infected Canadians in a Real-World Clinical Setting. 27th Annual Canadian Conference on HIV/AIDS Research (CAHR 2018), April 27, 2018, Vancouver BC
Pearce ME, Demerais L, Jongbloed KA, Christian WM, MacDonald H, Yoshida E, Pick N, Spittal PM, Klein MB. “It’d be another thing to live for”: Supporting HCV treatment and cure among Indigenous people impacted by substance use in Canadian cities. 27th Annual Canadian Conference on HIV/AIDS Research (CAHR 2018), April 29, 2018, Vancouver BC
Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB, on behalf of the Canadian Co-infection Cohort Investigators. Variation in Hepatitis C Virus Treatment Uptake in the Era of Direct-acting Antivirals. 27th Annual Canadian Conference on HIV/AIDS Research (CAHR 2018), April 26-29, 2018, Vancouver BC
Kronfli N, Nitulescu R, Cox J, Walmsley W, Cooper C, Gill MJ, Vachon ML, Martel-Laferriere V and Klein MB, on behalf of the Canadian Co-infection Cohort Investigators. Decreased hepatitis C (HCV) treatment uptake among HIV-HCV co-infected patients with a history of incarceration: Missed opportunities for care. 7th Canadian Symposium on HCV, 9 February 2018, Toronto, Ontario
Rossi C, Saeed S, Klein MB. Real-world effectiveness of interferon-free, all-oral direct-acting antivirals in the setting of hepatitis C and HIV co-infection. 7th Canadian Symposium on HCV, 9 February 2018, Toronto, Ontario
2017
Kronfli N, Bhatnagar SR, Hull M, Moodie E, Cooper C, Pick N, Walmsley S, Vachon ML, Martel-Laferriere V, Gill MJ, Klein MB, on behalf of the Canadian Co-Infection Cohort Investigators. Trends in Cause-Specific Mortality in HIV-hepatitis C (HCV) co-infected patients in Canada (2003 – 2016): Early Impact of HCV Therapy. 9th IAS Conference on HIV Science (IAS 2017), 24 July 2017, Paris, France
Saeed S, Strumpf EC, Moodie EEM, Klein MB. Varying Direct Acting Antiviral Initiation Rates in Vulnerable HIV-HCV Co-Infected Populations in Canada. 21st International Workshop on HIV and Hepatitis Observational Databases (IWHOD 2017). March 2017, Lisbon, Portugal
2016
McLinden T, Moodie EEM, Hamelin A-M, Paradis G, Rourke SB, Cooper C, Klein MB, Cox J. Injection drug use, low income, and severe food insecurity in HIV-HCV co-infected individuals in Canada: a mediation analysis. HIV Endgame II: Stopping the Syndemics that Drive HIV Conference. Toronto, Ontario
Rossi C, Hull M, Cox J, Cooper C, Martel-Laferrière V, Klein MB. Rates and Risk Factors for Hepatitis C Re-Infection or Late Relapse after Sustained Virologic Response to Treatment among HIV Co-Infected Canadians. 25th Annual Canadian Conference on HIV/AIDS Research, 13 May 2016, Winnipeg, Manitoba
Sebastiani G, Wagner J, Klein MB, Pantopoulos K. Association of Fibroblast Growth Factor 23 and Serum Ferritin with Liver Fibrosis diagnosed by Transient Elastography in HIV/HCV Co−Infected Patients. 25th Annual Canadian Conference on HIV/AIDS Research, 13 May 2016, Winnipeg, Manitoba
Costiniuk C, Brunet L, Rollet-Khurajec K, Cooper CL, Walmsley S, Gill MJ, Martel-Laferriere V, Tyndall M, Klein MB. Tobacco Smoking is Not Associated with Accelerated Liver Disease in HIV-Hepatitis C Co-Infection: A Longitudinal Cohort Analysis. 25th Annual Canadian Conference on HIV/AIDS Research, 13 May 2016, Winnipeg, Manitoba
Moqueet N, Kanagaratham C, Radzioch D, Saeed S, Platt RW, Klein MB. Developing a Prognostic Model for Significant Liver Fibrosis in HIV-Hepatitis C (HCV) Co-Infected Individuals from the Canadian Co-infection Cohort Study. 2016 Annual Meeting Canadian Association for the Study of the Liver (CASL)/CDDW. February 26 – 29, 2016, Montreal, Quebec
Rossi C, Hull M, Cox J, Cooper C, Martel-Laferriere V, Pick N, Walmsley SL, Montaner JS, Klein MB. Risk of Hepatitis C Virus Re-Infection or Late Relapse after Sustained Virologic Response to Interferon-based Therapy in HIV Co-infected Canadians. 5th Canadian Symposium on HCV, Montreal, 26 February, 2016
2015
Brunet L, Moodie EEM, Young J, Walmsley S, Hull M, Cooper C, Klein MB for the Canadian Co-Infection Cohort Study Investigators. A longitudinal analysis of liver fibrosis progression among NNRTI and PI users in the Canadian Co-infection Cohort Study. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, British Columbia. July 19-22, 2015
Saeed S, Rollet K, Strumpf EC, Klein MB for the Canadian Co-Infection Cohort Study Investigators (CTN222). How generalizable are Direct Antiviral Agents (DAA) trials for real world people co-infected with HIV/Hepatitis C? 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, British Columbia. July 19-22, 2015
Moqueet N, Kanagaratham C, Radzioch D, Saeed S, Platt RW, Klein MB. Developing a Prognostic Model for Significant Liver Fibrosis in HIV-Hepatitis C (HCV) Co-Infected Individuals from the Canadian Co-infection Cohort Study. 48th Annual Meeting of the Society for Epidemiologic Research (SER 2015). Denver, Colorado. 16-19 June, 2015
Rossi C, Moodie EEM, Rollet-Kurhajec KC, Cox J, Cooper C, Hull M, Walmsley S, Gill J, Rachlis A, and Klein MB for the Canadian Co-infection Cohort Study Investigators. Injection cocaine use as a risk factor for chronic renal impairment among hepatitis C and HIV co-infected patients receiving care. 48th Annual Meeting of the Society for Epidemiologic Research (SER 2015). Denver, Colorado. 16-19 June, 2015
Rossi C, Moodie EEM, Rollet-Kurhajec KC, Cox J, Cooper C, Hull M, Walmsley S, Gill J, Rachlis A, and Klein MB for the Canadian Co-infection Cohort Study Investigators. Cocaine Use and Chronic Kidney Disease in a HCV-HIV Co-Infected Cohort. 24th Annual Canadian Conference on HIV/AIDS Research (CAHR 2015), Toronto, Ontario, April 30 – May 3, 2015
Moqueet N, Platt R, Hull M, Cooper C, Walmsley S, Klein MB, for the Canadian Co-infection Cohort. Favourable IFNL3 Genotypes and Liver Fibrosis in HIV-Hepatitis C (HCV) Co-Infected Individuals from the Canadian Co-Infection Cohort. 24th Annual Canadian Conference on HIV/AIDS Research (CAHR 2015), Toronto, Ontario, April 30 – May 3, 2015
2014
Brunet L, Moodie EEM, Cox J, Pick N, Hull M, Conway B, Cooper C, Walmsley S, Tyndall M, Klein MB. Does Opioid Use Play a Role in Progression of Liver Fibrosis in HIV-Hepatitis C (HCV) Co-Infection? 23nd Annual Canadian Conference on HIV/AIDS Research, St John’s, NL, Canada, May 1-4, 2014
Rossi C, Rollet K, Brunet L, Klein MB. Association between HCV RNA status and all-cause mortality in a cohort of HCV-HIV co-infected Canadians. 3rd Canadian Symposium on Hepatitis C Virus, Toronto, February 2014
2013
Yeung MW, Rollet K, Cooper C, Cox J, Hull M, Pick N, Rachlis A, Tyndall M, Walmsley S, Klein MB for the Canadian Co-Infection Cohort (CTN222). Overcoming hepatitis C: changes in quality of life, healthcare use, and substance use in HIV-coinfected patients after HCV therapy. 22nd Canadian Conference on HIV/AIDS Research, Vancouver, April 2013
Klein MB, Rollet K, Young J, Walmsley S, Rachlis A, Moodie EEM for the Canadian Co-Infection Cohort (CTN222). Liver fibrosis progression in HIV/Hepatitis C Virus Co-infection: Can immunosuppression before antiretroviral therapy be overcome? International Workshop on HIV Observational Databases, Cavtat, Croatia, April 2013
Moqueet N, Young J, Lisle C, Carter R, Klein M for the Canadian Co-Infection Cohort (CTN222). Favourable IL28B genotypes are associated with Spontaneous Clearance but not aboriginal ancestry in Canadian HIV/HCV co-infected individuals from the Canadian Co-infected Cohort. Canadian Association for the Study of the Liver, Victoria, March 2013
Rollet K, Moodie E, Pick N, Walmsley S, Cooper C, Cox J, Potter M, Gill J, Klein MB for the Canadian Co-Infection Cohort (CTN222). Female gender is associated with liver fibrosis progression in antiretroviral treated HIV-HCV co-infected patients. 3rd International Workshop on HIV & Women, Toronto, January 2013
2012
Moqueet N, Young J, Klein MB for the Canadian Co-Infection Cohort (CTN222). IL28B and spontaneous clearance in HIV/HCV co-infected individuals from the Canadian Co-infection Cohort. Canadian Society for Epidemiology and Biostatistics National Student Conference, Saskatoon, May 2012
Brunet L, Moodie EE, Rollet K, Tyndall M, Potter M, Conway B, Walmsley S, Pick N, Cooper C, Cox J, Klein MB for the Canadian Co-Infection Cohort (CTN222). Marijuana smoking does not appear to cause progression of liver fibrosis in the Canadian HIV/HCV Co-infection Cohort Study. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012
Klein MB, Rollet K, Saeed S, Cooper C, Conway B, Cox J, Gill J, Pick N, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222).Mortality in HIV-Hepatitis C virus (HCV) co-infected persons enrolled in the Canadian Co-infection Cohort study in comparison to the Canadian population. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012
Klein MB, Rollet K, Saeed S, Moodie E, Cox J, Cooper C, Gill J, Hull M, Potter M, Walmsley S for the Canadian Co-Infection Cohort (CTN222).Who needs direct acting antivirals for hepatitis C virus (HCV)? Challenges faced in advancing HCV therapy with direct acting antivirals (DAAs) in HIV-HCV co-infected persons. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012
Potter M, Young J, Rollet K, Cox J, Walmsley S, Cooper C, Tyndall M, Montaner J, Conway B, Pick N, Côté P, Rouleau D, Klein MB for the Canadian Co-Infection Cohort (CTN222). Estimating variations between health care centres in the uptake of hepatitis C virus (HCV) treatment in HIV-HCV co-infected patients. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012
Melendez-Pena C, Habayeb M, Saeed S, Conway B, Cooper C, Ward B, Ndao M, Klein MB for the Canadian Co-Infection Cohort (CTN222). Serum biomarkers predictive of fibrosis by proteomic fingerprinting in HIV-1/HCV co-infection. 21st Canadian Conference on HIV/AIDS Research, Montreal, April 2012
2011
Brunet L, Moodie E, Rollet K, Tyndall M, Cooper C, Walmsley S, Pick N, Klein MB for the Canadian Co-infection Cohort (CTN222). Heroin use is associated with progression to cirrhosis in HIV-HCV coinfected patients. (Abstract O_O3) 7th International HIV and Hepatitis Co-infection Workshop, Milan, June 2011
Hull M, Yang H, Odueyuao A, Saeed S, Montaner J, Klein MB for the Canadian Co-infection Cohort Investigators (CTN222). Factors associated with discordance between absolute CD4 cell count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. International HIV and Hepatitis Co-infection Workshop, Milan, June 2011
Pick N, Castillo E, Rollet K, Burdge D, Saeed S, Klein MB, Canadian HIV-HCV Co-infection Cohort (CTN222). Gender and liver disease progression in HIV-hepatitis C co-infection. 1st International Workshop on HIV & Women, Washington DC, January 2011
2010
Hull M, Yang H, Odueyungbo A, Saeed S, Montaner J, Klein MB for the Canadian Co-infection Cohort Investigators (CTN222). Factors associated with discordance between absolute CD4 count and CD4 percentage in HIV/Hepatitis C (HCV) co-infected patients. 6th International HIV and Hepatitis Co-infection Workshop, Tel Aviv, Isreal, June 2010
2008
Klein MB, Rouleau D, Cox J, Saeed S, Murphy T for the Canadian Co-Infection Cohort Study (CTN222). A detailed profile of HIV-Hepatitis C Virus (HCV) co-infected persons receiving care in Montreal: The Canadian HIV-Hepatitis C Cohort Pilot Study. 17th Canadian Conference on HIV/AIDS Research, Montreal, April 2008
2006
Klein MB, Murphy T, Lalonde RG. The contribution of HAART regimens to liver fibrosis progression in HIV-Hepatitis C co-infection (ABS0177). 15th Canadian Conference on HIV/AIDS Research, Quebec City, May 2006
Klein MB, Murphy T, Lalonde RG. The contribution of HAART regimens to liver fibrosis progression in HIV-hepatitis C co-infection. 10th International Workshop on HIV Observational Databases, Madrid, March 2006
2005
Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a Simple Model for Predicting Liver Fibrosis in HIV/Hepatitis C (HCV) Co-infected Patients. 14th Canadian Conference on HIV/AIDS Research, Vancouver, May 2005. (Abstract 217) CMAJ; 16(Supp A):39A
Klein MB, Al-Mohri H, Murphy T, Kato C, Rouleau D. Contribution of Drug Use and Lifestyle to Hepatic Fibrosis in HIV-hepatitis C (HCV) Co-infection. 14th Canadian Conference on HIV/AIDS Research, Vancouver, May 2005. (Abstract 219) CMAJ; 16(Supp A):39-40A